Syndax Pharmaceuticals (SNDX) EBITDA (2016 - 2020)
Historic EBITDA for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Q4 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' EBITDA fell 3980.99% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 2412.97%. This contributed to the annual value of -$339.7 million for FY2024, which is 4771.3% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported EBITDA of -$19.9 million as of Q4 2020, which was down 3980.99% from -$19.9 million recorded in Q3 2020.
- Syndax Pharmaceuticals' EBITDA's 5-year high stood at -$8.4 million during Q2 2016, with a 5-year trough of -$19.9 million in Q4 2020.
- Moreover, its 5-year median value for EBITDA was -$15.1 million (2017), whereas its average is -$15.5 million.
- In the last 5 years, Syndax Pharmaceuticals' EBITDA plummeted by 15710.14% in 2016 and then surged by 2652.46% in 2019.
- Over the past 5 years, Syndax Pharmaceuticals' EBITDA (Quarter) stood at -$11.1 million in 2016, then tumbled by 74.93% to -$19.5 million in 2017, then increased by 0.8% to -$19.3 million in 2018, then increased by 26.52% to -$14.2 million in 2019, then tumbled by 39.81% to -$19.9 million in 2020.
- Its EBITDA was -$19.9 million in Q4 2020, compared to -$19.9 million in Q3 2020 and -$16.6 million in Q2 2020.